Epidermal growth factor receptor mutations in non-small cell lung cancer: A basic science discovery with immediate clinical impact

Research output: Contribution to journalArticle

12 Scopus citations


A large body of preclinical work suggested that the epidermal growth factor receptor (EGFR) would be a successful target for therapy against non-small cell lung cancer (NSCLC), and this led to the development of oral, selective EGFR tyrosine kinase inhibitors (TKI) that improve symptoms and survival in patients with advanced NSCLC. However, not all patients benefit from this treatment, and there has been great interest in identifying the molecular correlates that predict for response to these agents. The recent detection of somatic mutations in EGFR that predict for response to the EGFR tyrosine kinase inhibitors has excited the scientific community. This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies.

Original languageEnglish (US)
Pages (from-to)139-149
Number of pages11
JournalAmerican Journal of the Medical Sciences
Issue number3
StatePublished - Mar 1 2006



  • Epidermal growth factor receptor
  • Lung neoplasms
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this